#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Veru

This article discusses a clinical trial investigating the effectiveness of 2LVERU® JUNIOR and 2LVERU®, two medications containing Specific Nucleic Acid SNA-VERU, in treating non-genital warts. The study aims to compare these treatments with a placebo group to determine their efficacy in wart disappearance over a 6-month period. This randomized, placebo-controlled, double-blind study, known as the EVAsION Study, focuses on patients aged 3 years and older with common, plantar, or flat warts.

Table of Contents

What is SPECIFIC NUCLEIC ACID SNA-VERU?

SPECIFIC NUCLEIC ACID SNA-VERU, also known as SNA-VERU or SPECIFIC NUCLEIC ACID – VERRUCA HUMAN PAPILLOMAVIRUS, is an active ingredient in medications designed to treat non-genital warts[1]. It is part of a group of substances called nucleic acids, which are important components of our genetic material[1].

How Does It Work?

SNA-VERU works alongside other active ingredients such as interferon alfa, interleukin-1, interleukin-2, and ribonucleic acid. These substances are believed to help boost the body’s immune response against the virus causing warts[1]. By targeting the specific genetic material of the human papillomavirus (HPV) that causes warts, SNA-VERU may help the body fight off the infection more effectively.

What Medical Conditions Does It Treat?

The primary medical condition that SPECIFIC NUCLEIC ACID SNA-VERU is designed to treat is non-genital warts infection[1]. This includes several types of warts:

  • Common warts (Verruca vulgaris)
  • Plantar warts (Verruca plantaris) – warts on the soles of the feet
  • Flat warts (Verruca plana) – smoother, flatter warts that can appear on the face or other parts of the body

Current Clinical Trial

A clinical trial is currently underway to evaluate the effectiveness of medications containing SNA-VERU. This trial, known as the EVAsION Study, is comparing two products: 2LVERU® JUNIOR and 2LVERU®, against a placebo[1]. The main goal is to see how well these treatments work in making warts disappear after 6 months of use.

How Is It Administered?

The medication containing SPECIFIC NUCLEIC ACID SNA-VERU comes in the form of granules in capsules that are meant to be opened. It is administered through oromucosal use, which means it’s applied to the mucous membranes of the mouth[1]. This method allows the medication to be absorbed into the bloodstream through the tissues in the mouth.

Dosage Information

The maximum daily dose of the medication is 380 mg, with a total maximum dose of 68.4 g over the course of treatment[1]. The treatment period typically lasts for 6 months.

Effectiveness and Safety

The ongoing clinical trial aims to determine how effective SNA-VERU is in treating warts. The researchers are looking at several factors:

  • How many warts disappear after 4 months and 6 months of treatment
  • Whether the warts come back 3 months after the treatment ends
  • How much pain patients experience during the study
  • Any side effects or safety concerns that arise during treatment[1]

Who Can Use This Treatment?

Based on the clinical trial information, this treatment may be suitable for:

  • Patients aged 3 years and older
  • People with common warts, plantar warts, or flat warts

However, the treatment may not be suitable for:

  • Pregnant or breastfeeding women
  • People with severe immune system disorders
  • Patients undergoing chemotherapy or radiotherapy
  • Those with known lactose intolerance[1]

It’s important to note that this information is based on an ongoing clinical trial. The full effectiveness and safety profile of SPECIFIC NUCLEIC ACID SNA-VERU will be better understood once the trial is completed and the results are analyzed.

Aspect Details
Study Type Randomized, placebo-controlled, double-blind clinical trial
Medications Tested 2LVERU® JUNIOR and 2LVERU®
Main Active Substance Specific Nucleic Acid SNA-VERU
Condition Treated Non-genital warts (common, plantar, and flat warts)
Primary Endpoint Wart disappearance at 6 months (end of treatment)
Treatment Duration 6 months
Eligible Age Group 3 years and older
Key Exclusions Recent wart treatments, immunosuppressive therapy, pregnancy, breastfeeding
Secondary Objectives Wart disappearance at 4 months, recurrence rates, pain evaluation, safety assessment

FAQ

  • What is the main objective of this clinical trial? The main objective is to compare the efficacy of 2LVERU® JUNIOR and 2LVERU® versus a placebo group in the disappearance of warts at the end of a 6-month treatment period.
  • Who can participate in this clinical trial? Patients aged 3 years and older with common warts, plantar warts, or flat warts can participate. They must be able to understand and follow the study requirements and provide informed consent.
  • What are the key components of the medications being tested? The medications contain several active substances, including Interferon Alfa, Interleukin-1, Interleukin-2, Ribonucleic Acid, Specific Nucleic Acid SNA-HLA II, and Specific Nucleic Acid SNA-VERU.
  • How long does the treatment last in this study? The treatment period lasts for 6 months, with follow-up evaluations at 4 months and 3 months after the end of treatment.
  • What are some of the secondary objectives of the study? Secondary objectives include comparing wart disappearance at 4 months, evaluating different levels of wart disappearance, assessing wart recurrence 3 months post-treatment, comparing pain related to warts, and monitoring safety issues.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Veru

  • Study on the Effectiveness of Interferon Alfa, Interleukin-1, and Interleukin-2 in Treating Non-Genital Warts in Patients

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Placebo-controlled: A study design where some participants receive an inactive substance (placebo) instead of the active treatment, allowing researchers to compare the effects of the actual medication.
  • Double-blind: A study method where neither the participants nor the researchers know who is receiving the actual treatment or the placebo, reducing potential bias in the results.
  • Verruca vulgaris: The medical term for common warts, which are small, rough growths on the skin caused by a virus.
  • Verruca plantaris: The medical term for plantar warts, which are warts that appear on the soles of the feet.
  • Verruca plana: The medical term for flat warts, which are smoother and flatter than other types of warts.
  • Immunosuppressive treatment: Medications that lower the body's immune response, often used to treat autoimmune diseases or prevent organ rejection after transplants.
  • Specific Nucleic Acid SNA-VERU: A component of the study medication that is specifically designed to target the human papillomavirus responsible for warts.
  • Interferon Alfa: A protein that helps the immune system fight viral infections and is one of the active substances in the study medication.
  • Interleukin-1 and Interleukin-2: Proteins that play important roles in the immune system's response to infections and are components of the study medication.
  • Adverse events (AEs): Any unfavorable or unintended sign, symptom, or disease that occurs during the study, whether or not it is related to the treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-interferon-alfa-interleukin-1-and-interleukin-2-in-treating-non-genital-warts-in-patients/